Table 5.
Numbers of participants grouped by disease duration (<5 years, 5 to <10 years and >10 years)
| <5 years (n = 327–330) | 5 to <10 years (n = 170–171) | ≥10 years (n = 157–158) | Chi2 between groups | |
|---|---|---|---|---|
| ESSPRI ≥5 | 185/330 (56.1%) | 103/171 (60.2%) | 103/158 (65.2%) | Chi2 = 3.77, P = 0.15 |
| ESSDAI ≥5 | 139/330 (42.1%) | 71/171 (41.5%) | 65/157 (41.4%) | Chi2 = 0.03, P = 0.99 |
| Anti-Ro+ | 291/328 (88.7%) | 158/170 (92.9%) | 139/158 (88.0%) | Chi2 = 2.76, P = 0.25 |
| Usf >0a | 216/330 (65.5%) | 116/171 (67.8%) | 83/158 (52.5%) | Chi2 = 9.99, P = 0.007 |
Data was available from 659 particpants (missing disease duration data n = 29) and is set out for ESSPRI, ESSDAI, anti-Ro antibody status and usf. Numbers with available data are indicated in the Table.
a
Disease duration correlated inversely with usf (n = 659, Spearman correlation rho = −0.108, P = 0.006). ESSPRI: EULAR Sjögren’s Syndrome Patient-Reported Index; ESSDAI: EULAR Sjögren’s Syndrome Disease Activity Index.